> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Remove Amarin Corp. Patent from Orange Book: Petition
- URL: https://www.fdaweb.com/remove-amarin-corp-patent-from-orange-book-petition/
- Published: 2019-07-10T12:00:00.000Z
- Updated: 2026-09-15T01:37:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144496

Medical Research Collaborative is petitioning FDA to have an Amarin Corp. patent removed from the *Orange Book* for being improperly listed. The 7/8 [petition](https://www.regulations.gov/contentStreamer?documentId=FDA-2019-P-3265-0001&attachmentNumber=1&contentType=pdf&ref=fdaweb.com) says the Amarin patent for highly purified ethyl EPA and other EPA derivatives “does not claim an approved method of using the drug, promotes unapproved uses, and in fact eschews the only approved use for icosapent ethyl (aka ‘Vascepa’), namely to treat hypertriglyceridemia. Further, its claims describe a product that is impossible to make, relying on the judicial exception of an abstract idea, and is materially different from the manufactured and sold drug, ‘Vascepa.’”